Venturi Wealth Management LLC Has $1.15 Million Stock Holdings in Zoetis Inc. $ZTS

Venturi Wealth Management LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 39.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,353 shares of the company’s stock after selling 4,862 shares during the quarter. Venturi Wealth Management LLC’s holdings in Zoetis were worth $1,147,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Brighton Jones LLC grew its holdings in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares in the last quarter. Wedmont Private Capital grew its holdings in Zoetis by 5.0% in the 1st quarter. Wedmont Private Capital now owns 2,563 shares of the company’s stock valued at $422,000 after buying an additional 122 shares in the last quarter. Miracle Mile Advisors LLC grew its holdings in Zoetis by 42.1% in the 1st quarter. Miracle Mile Advisors LLC now owns 2,373 shares of the company’s stock valued at $391,000 after buying an additional 703 shares in the last quarter. OLD National Bancorp IN grew its holdings in Zoetis by 28.4% in the 1st quarter. OLD National Bancorp IN now owns 1,993 shares of the company’s stock valued at $328,000 after buying an additional 441 shares in the last quarter. Finally, Courier Capital LLC grew its holdings in Zoetis by 29.6% in the 1st quarter. Courier Capital LLC now owns 1,972 shares of the company’s stock valued at $325,000 after buying an additional 450 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZTS has been the topic of several analyst reports. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Stock Performance

Shares of ZTS stock opened at $143.61 on Thursday. The business’s 50-day moving average price is $149.41 and its 200-day moving average price is $154.74. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The firm has a market capitalization of $63.65 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 2.29 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the firm posted $1.56 earnings per share. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.